ETHICAL AND GENETIC ASPECTS REGARDING PRESYMPTOMATIC TESTING FOR NEURODEGENERATIVE DISEASES

Area of Science:

• Neurology
• Genetics
• Medical Ethics

Background:

• Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, Huntington's) have insidious onsets and long presymptomatic stages.
• Significant neuronal loss can occur before clinical symptoms manifest, as seen in Parkinson's disease.
• Genetic mechanisms like trinucleotide repeat expansions are implicated in several inherited neurodegenerative disorders.

Purpose of the Study:

• To explore the implications of presymptomatic diagnosis in progressive neurodegenerative diseases.
• To address the ethical considerations surrounding early disease prediction.
• To weigh the potential benefits of early diagnosis against psychological and social risks.

Main Methods:

• Review of genetic mechanisms in hereditary neurodegenerative diseases.
• Analysis of presymptomatic diagnostic capabilities (e.g., CAG repeat analysis in Huntington's disease).
• Discussion of ethical issues related to predictive genetic testing.

Main Results:

• Presymptomatic diagnosis is feasible for certain neurodegenerative diseases through genetic analysis.
• Early detection precedes significant clinical manifestation by many years.
• Trinucleotide repeat expansions are a common genetic mechanism.

Conclusions:

• Presymptomatic testing for neurodegenerative diseases presents significant ethical dilemmas.
• Potential psychological trauma, lifestyle changes, and discrimination risks must be considered.
• The benefits of early diagnosis must be carefully balanced against potential harms.